Objective: To present clinical and laboratory data of a Brazilian social program for cancer fertility preservation. Methods: We carried out a descriptive observational study between July 2011 and December 2018. 246 patients were included from a social program in a private assisted reproduction clinic in Santo André/Brazil for oocyte cryopreservation before starting oncological treatment. Results: 246 cancer patients resorted to fertility preservation before initiating cancer treatment. These were diagnosed with 27 different types of cancer, and the breast type is the most prevalent. 2528 MII oocytes (mean of 10.3 oocytes per patient) were vitrified. Four patients thawed their oocytes to submit in vitro fertilization, three had embryos transferred and one achieved pregnancy. Conclusion: Preservation of fertility offers patients, especially at reproductive age, a viable way to perform their cancer treatment without compromising future gestation. It is important that professionals duly counsel oncological patients so, if they wish, they can have the possibility to guarantee her fertility preserved.

Objective: To compare laboratory results of embryo development from late matured oocytes in relation to mature oocytes in D+0.Methods: We carried out a cross-sectional study during the period from January to December 2018, in which we collected data through medical records analysis. 913 oocytes were collected and divided into 3 groups: group 1 -643 MII oocytes; group 2 -119 MI oocytes and; group 3 -151 PI oocytes. These studied oocytes were from different maternal ages and infertility factors. The analyzed variables were fertilization rate, embryo cleavage, top quality embryos on the third day of development, blastocyst stage, top quality blastocysts, euploid blastocysts, top quality blastocysts and gestation. We documented the data, and performed the statistical analysis using the chisquare test (p<0.05).Results: All MII oocytes were injected (643); 103/119 MI oocytes and 88/151 PI oocytes that matured late in D + 1, were also injected. The fertilization rate of the three groups did not present statistical difference. The oocytes of group 1 had a statistically proven better prognosis than oocytes from groups 2 and 3 when compared, respectively, embryo cleavage (p=0.000), top quality embryos on the third day of development (p=0.000) and blastocyst formation rate (p=0.004). In the LMO group, there were no euploid embryos and, therefore, there no embryo transfer. Conclusion:Although late matured oocytes have made blastocyst formation possible, even if in low rates, there were no viable embryos for transfer.

Objective: The aim of the present study was to investigate and to compare the relations of anti-Mullerian with the prognostic parameters and the outcome of assisted reproductive treatment. Methods: Prospective longitudinal study. A total of one hundred and twelve infertile women. Inclusion criteria: i) both ovaries present, ii) no current or past diseases affecting ovaries or gonadotropin or sex steroid secretion, clearance, or excretion, iii) no current hormone therapy, iv) adequate visualization of ovaries at transvaginal ultrasound scans, and v) total number of small antral follicles (3-12 mm in diameter) between 1 and 32 follicles. On cycle day 3, woman underwent blood sampling for serum FSH and AMH measurement and a transvaginal ovarian ultrasound scan for follicle measurement. Ongoing pregnancy was evaluated as biochemical pregnancy and observation of gestational sac(s). Results: Mean age of 36.13 ± 4.65 years old, BMI 21.59 ± 2.78 kg/m2, and length of infertility of 2.88 ± 2.36 years. Their ovaries had an average of 13.74 ± 6.0 antral follicles and AMH was 2.49 ± 1.98 ng / mL. A significant relationship of AMH with age (r = -0.37 P <.01) , with FSH (r = -0.22, P <.01) , with AFC (r = 0.74, P <.00001), with smoking (P <.009), with SOP (P <.00001), with the total dose of the drug during stimulation ovarian (r = -0.36, P <.0004), with abortion (P <.05) and with the ongoing pregnancy (P <.05). Conclusion: AMH is a marker of quantitative and qualitative aspects of the ovarian reserve.

Objective: To assess the recovery of thawed blastocysts submitted to quarter laser assisted hatching and examine potential correlations between the procedure and pregnancy rates.Methods: This cross-sectional study included only single-blastocyst transfers performed from July 2017 to December 2018. A total of 765 blastocysts were thawed and immediately submitted to quarter laser assisted hatching in the zona pellucida; they were subsequently incubated for three hours until transfer time, at which time they were examined for collapse or expansion; expanded blastocysts were further evaluated for herniation. The Chi-square test was used in statistical analysis.Results: 627 blastocysts expanded (81.9%) and yielded a pregnancy rate of 40% (251/627). 138 blastocysts collapsed after thawing (18.0%) and yielded a pregnancy rate of 25.4% (35/138) (p=0.001). Additional analysis of the subgroup of expanded blastocysts revealed that the 385 herniated blastocysts (61.4%) yielded a pregnancy rate of 43.9% (169/385). The remaining 242 non-herniated blastocysts (38.6%) yielded a pregnancy rate of 33.9% (82/242) (p=0.013). Statistical significance was attributed to events with a p<0.05. Conclusion:Quarter laser assisted hatching is a safe, valid, and relatively easy-to-use procedure for thawed blastocysts. Blastocysts that expanded and herniated after quarter laser assisted hatching presented statistically superior results.